Back to mobile site
Get it on Google Play

BeOne's Brukinsa cuts lymphoma progression risk by 43% in trial

June 30, 2026 6:00 AM EDT Send to a Friend
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235) announced positive topline results from its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login